The state of complement in COVID-19

Behdad Afzali; Marina Noris; Bart N. Lambrecht; Claudia Kemper

doi:10.1038/s41577-021-00665-1

The state of complement in COVID-19

Behdad Afzali^*, Marina Noris, Bart N. Lambrecht, Claudia Kemper

^*Corresponding author for this work

Pulmonary Medicine

Research output: Contribution to journal › Article › Academic › peer-review

61 Citations (Scopus)

9 Downloads (Pure)

Abstract

Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.

Original language	English
Pages (from-to)	77-84
Number of pages	8
Journal	Nature Reviews Immunology
Volume	22
Issue number	2
Early online date	15 Dec 2021
DOIs	https://doi.org/10.1038/s41577-021-00665-1
Publication status	Published - Feb 2022

Bibliographical note

Funding Information:
Research described in this article was supported (in part) by the Intramural Research Program of the US National Institute of Diabetes and Digestive and Kidney Diseases (project number ZIA/DK075149 (B.A).) and the US National Heart, Lung, and Blood Institute (project number ZIA/Hl006223 (C.K.)), by an FWO COVID-19 grant to B.N.L., and by a COVID-19 grant from the Fondazione Italcementi Cav. Lav. CARLO PESENTI to M.N.

Publisher Copyright:
© 2021, Springer Nature Limited.

Access to Document

10.1038/s41577-021-00665-1

The state of complement in COVID-19Final published version, 2.74 MBLicence: Unspecified

https://www.nature.com/articles/s41577-021-00665-1.pdf

Cite this

@article{c4ae2e981605450280ad766af3b861ff,

title = "The state of complement in COVID-19",

abstract = "Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.",

author = "Behdad Afzali and Marina Noris and Lambrecht, {Bart N.} and Claudia Kemper",

note = "Funding Information: Research described in this article was supported (in part) by the Intramural Research Program of the US National Institute of Diabetes and Digestive and Kidney Diseases (project number ZIA/DK075149 (B.A).) and the US National Heart, Lung, and Blood Institute (project number ZIA/Hl006223 (C.K.)), by an FWO COVID-19 grant to B.N.L., and by a COVID-19 grant from the Fondazione Italcementi Cav. Lav. CARLO PESENTI to M.N. Publisher Copyright: {\textcopyright} 2021, Springer Nature Limited.",

year = "2022",

month = feb,

doi = "10.1038/s41577-021-00665-1",

language = "English",

volume = "22",

pages = "77--84",

journal = "Nature Reviews Immunology",

issn = "1474-1733",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - The state of complement in COVID-19

AU - Afzali, Behdad

AU - Noris, Marina

AU - Lambrecht, Bart N.

AU - Kemper, Claudia

N1 - Funding Information: Research described in this article was supported (in part) by the Intramural Research Program of the US National Institute of Diabetes and Digestive and Kidney Diseases (project number ZIA/DK075149 (B.A).) and the US National Heart, Lung, and Blood Institute (project number ZIA/Hl006223 (C.K.)), by an FWO COVID-19 grant to B.N.L., and by a COVID-19 grant from the Fondazione Italcementi Cav. Lav. CARLO PESENTI to M.N. Publisher Copyright: © 2021, Springer Nature Limited.

PY - 2022/2

Y1 - 2022/2

N2 - Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.

AB - Hyperactivation of the complement and coagulation systems is recognized as part of the clinical syndrome of COVID-19. Here we review systemic complement activation and local complement activation in response to the causative virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and their currently known relationships to hyperinflammation and thrombosis. We also provide an update on early clinical findings and emerging clinical trial evidence that suggest potential therapeutic benefit of complement inhibition in severe COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85121549900&partnerID=8YFLogxK

U2 - 10.1038/s41577-021-00665-1

DO - 10.1038/s41577-021-00665-1

M3 - Article

C2 - 34912108

AN - SCOPUS:85121549900

SN - 1474-1733

VL - 22

SP - 77

EP - 84

JO - Nature Reviews Immunology

JF - Nature Reviews Immunology

IS - 2

ER -

The state of complement in COVID-19

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this